MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1

Enqi Li1, Jinli Zhang, Tianxiang Yuan

  • 1Department of Orthopaedic Trauma, TianJin Hospital, Jiefang Road No. 406, Hexi District, 300211, Tianjin, China, enqi_litj@163.com.

Insights

MicroRNA-145 (miR-145) acts as a tumor suppressor in osteosarcoma (OS). Lower miR-145 levels promote cancer progression by increasing Rho-associated protein kinase 1 (ROCK1) expression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are crucial regulators implicated in human cancer development.
  • Osteosarcoma (OS) is a primary bone malignancy with significant metastatic potential.

Purpose of the Study:

  • To investigate the role of miR-145 in osteosarcoma.
  • To identify the direct functional target of miR-145 in OS cells.

Main Methods:

  • Quantitative real-time PCR to assess miR-145 expression in OS tissues and cell lines.
  • Cell proliferation, migration, and invasion assays in MG-63 cells with enforced miR-145 expression.
  • Western blotting and luciferase reporter assays to validate ROCK1 as a direct target of miR-145.
  • Correlation analysis between miR-145 and ROCK1 expression in OS tissues.

Main Results:

  • miR-145 expression was significantly downregulated in osteosarcoma tissues and cell lines compared to normal controls.
  • Overexpression of miR-145 suppressed proliferation, migration, and invasion of MG-63 osteosarcoma cells.
  • Rho-associated protein kinase 1 (ROCK1) was identified as a direct functional target of miR-145 in OS.
  • Silencing ROCK1 mimicked the tumor-suppressive effects of miR-145, and ROCK1 expression was inversely correlated with miR-145 levels in OS tissues.

Conclusions:

  • miR-145 functions as a tumor suppressor in osteosarcoma.
  • The miR-145/ROCK1 axis plays a critical role in regulating osteosarcoma progression.
  • Targeting the miR-145 pathway may offer a therapeutic strategy for osteosarcoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K